Laidlaw's take on BRL sale from Uncle's Discord
Apr 1, 2024 17:43:33 GMT
sgard434, miamianne67, and 4 more like this
Post by lookingforatenbagger on Apr 1, 2024 17:43:33 GMT
Laidlaw: OPK: Divestment of portion of BR assets, a positive step forward for eventual transition to a drug developer pure play.
2024-03-29 01:16:29.850 GMT
Synopsis:
Our Take. This morning, OPK reported that they have divested part of BioReference Health assets to LabCorp for $237.5MM. Our takeaway is that this is a nicely executed BR asset divestiture and potentially a stepwise process that could maximize the value of the entire BR asset as OPK becomes a drug developer pure play.
The transaction will be on BR’s testing business focusing on clinical routine general diagnostics and reproductive and women’s health operation across the U.S. outside of the NY and NJ region. The focused geographic regions include FL, TX, and CA. Post transaction, OPK will retain a substantial portion of the BR, mainly specialty testing of urology, which includes 4K test and oncology with all lines of testing in the NY/NJ region, which OPK has a strong market share and better profitability.
Based on the diagnostics sales in 2023, annual revenue was ~$550MM and post transaction, ~$450MM prospectively still in OPK’s hand. Should the remaining BR operations become breakeven or profitable, OPK would have the option, if they choose, to further divest these assets and possibly at a higher multiple given its improved state.
We view today’s news positively as OPK has successfully divested part of its diagnostic assets at a reasonable price after the company streamlined and improved the diagnostic operations. This is a good beginning, in our opinion, as BR’s remaining assets could be more valuable and could potentially generate even greater value once OPK decides to further divest going forward. OPK is becoming a drug developer pure play.
We believe they have a rather promising drug pipeline led by the ModeX platform with partial support from the co-marketing revenue created by the growing Ngenla sales and indication expansion.
We also have observed that over recent history, OPK has a very good batting average of developing drugs successfully. They have gained approvals of three initially in-house developed drugs over the last decade. We are reiterating our Buy rating and $8.50 target price."
My bolding of original
2024-03-29 01:16:29.850 GMT
Synopsis:
Our Take. This morning, OPK reported that they have divested part of BioReference Health assets to LabCorp for $237.5MM. Our takeaway is that this is a nicely executed BR asset divestiture and potentially a stepwise process that could maximize the value of the entire BR asset as OPK becomes a drug developer pure play.
The transaction will be on BR’s testing business focusing on clinical routine general diagnostics and reproductive and women’s health operation across the U.S. outside of the NY and NJ region. The focused geographic regions include FL, TX, and CA. Post transaction, OPK will retain a substantial portion of the BR, mainly specialty testing of urology, which includes 4K test and oncology with all lines of testing in the NY/NJ region, which OPK has a strong market share and better profitability.
Based on the diagnostics sales in 2023, annual revenue was ~$550MM and post transaction, ~$450MM prospectively still in OPK’s hand. Should the remaining BR operations become breakeven or profitable, OPK would have the option, if they choose, to further divest these assets and possibly at a higher multiple given its improved state.
We view today’s news positively as OPK has successfully divested part of its diagnostic assets at a reasonable price after the company streamlined and improved the diagnostic operations. This is a good beginning, in our opinion, as BR’s remaining assets could be more valuable and could potentially generate even greater value once OPK decides to further divest going forward. OPK is becoming a drug developer pure play.
We believe they have a rather promising drug pipeline led by the ModeX platform with partial support from the co-marketing revenue created by the growing Ngenla sales and indication expansion.
We also have observed that over recent history, OPK has a very good batting average of developing drugs successfully. They have gained approvals of three initially in-house developed drugs over the last decade. We are reiterating our Buy rating and $8.50 target price."
My bolding of original